SEC Filing Summary: Aspire Biopharma Holdings, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aspire Biopharma Holdings, Inc. (the "Company") on September 8, 2026. The Company is incorporated in Delaware and its common stock (ASBP) and warrants (ASBPW) trade on The Nasdaq Stock Market LLC. The report primarily addresses a corporate name change and the issuance of a press release.
Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on corporate governance and administrative changes rather than financial performance.
Material Changes
- Corporate Name Change: Effective September 8, 2026, the Company changed its name from "Aspire Biopharma Holdings, Inc." to "Aspire-Lakewood Holdings, Inc." via a Certificate of Amendment filed with the Delaware Secretary of State.
- Stockholder Approval: No stockholder approval was required for this amendment as it solely concerned a name change.
- Trading Symbol: The trading symbol on Nasdaq remains "ASBP".
- Stock Certificates: Existing stock certificates remain valid, and no action is required by stockholders holding shares in book-entry form or through nominees.
Guidance, Outlook, and Risks
The filing references a press release issued on September 9, 2026 (Exhibit 99.1), but the text of the press release is not included in the provided content. Consequently, no specific guidance, management commentary, risks, or contingencies can be summarized from this document. The name change itself is stated not to affect stockholder rights.
Key Facts for Investor Verification
- Verify the new corporate name "Aspire-Lakewood Holdings, Inc." in future filings and market data.
- Confirm that the trading symbol "ASBP" remains unchanged on Nasdaq.
- Review the attached press release (Exhibit 99.1) for details on the strategic rationale behind the name change.
- Note that the CUSIP number for the common stock remains unchanged.